| Record Nr. | UNINA9910647496303321 |
|-------------------------|---|
| Titolo | COVID-19 drug development : recent advances, new perspectives and applications / / edited by Arli Aditya Parikesit |
| Pubbl/distr/stampa | London : , : IntechOpen, , [2022] ©2022 |
| Descrizione fisica | 1 online resource (166 pages) : illustrations |
| Disciplina | 614.59241 |
| Soggetti | COVID-19 (Disease) |
| Lingua di pubblicazione | Inglese |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Nota di bibliografia | Includes bibliographical references. |
| Nota di contenuto | Introductory Chapter: Current Perspective of COVID-19 Drugs 22 Pluralism Medical Treatment, Prevention, and Control of COVID-19 Infection and Its Long-Sufferings among the Older Adults in the Northeast of Thailand from 2019 to 2022 142 3. Baricitinib in the Treatment of COVID-19 53 4. New Perspective and Applications of Homeopathy in Treating COVID-19 Symptoms 28 5. Treatments for the Infection by SARS-CoV-2 49 6. Inclusive Review on Existing Treatment and Management Modalities for COVID-19 39 7. COVID- 19: From Pathophysiology to Treatment 35 8. COVID-19 Drug Development: Role of Drug Repurposing 16. |
| Sommario/riassunto | COVID-19 is a rampant worldwide problem. It is caused by the SARS- CoV-2 virus and is manifest in different variants. The Delta variant compromised existing therapeutic and preventive options for this disease and is beginning to be replaced by the Omicron variant. Through pharmaceutical biotechnology, three different treatment approaches to COVID-19 have been developed: computer-aided drug design (CADD); rational drug design in the wet lab; and the advanced drug delivery system. These approaches are heavily influenced by advances in life sciences, such as the development of structural bioinformatics, the establishment of nanobiotechnology as a standard approach in drug design, and major advances in structural biology such as the development of the CryoEM method. This book will focus on providing possible solutions to the ongoing COVID-19 pandemic in |

1.